tbuckley/cabot-search huggingface dataset:
Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
Authors: M.H. Hong, M.H. Kim, S.-Y. Kim, S.G. Heo, H.-N. Kang, C.-W. Park, J.C. Barrett, D. Stetson, J. Chmielecki, A. Markovets, H.R. Kim, B.C. Cho
Journal: Annals of Oncology (2018)
Inhibition of glycolysis: Novel therapy for ovarian cancer
Authors: Angela Kueck, Lijun Tan, Milheon Choi, J. Rebecca Liu
Journal: Cancer Research (2005)

3085  Objectives: Resveratrol (3,5,4’-trihydroxystilbene), a natural phytoalexin found in red wine, grapes, and other dietary sources, has anti-neoplastic activity. We have previously demonstrated that resveratrol induces autophagic cell death (type II programmed cell death) in ovarian cancer cells. Autophagy is induced in mammalian cells in response to amino acid or glucose deprivation. Cancer cells exhibit increased rates of glycolysis as compared to normal cells, and have increased susceptibility to cell death induced by glucose deprivation. The purpose of this study was to determine if resveratrol induced autophagy in ovarian cancer cells is due to inhibition of glucose uptake, and to determine the therapeutic effect of resveratrol in vivo. Methods: Eight ovarian cancer cell lines were incubated with media containing glucose, resveratrol, or 2-deoxyglucose (2-DOG). Growth inhibition was determined using the sulforhodamine assay. Glucose uptake was analyzed with the 3H-2-DOG assay. Activation of AKT and translocation of the Glut1 receptor was determined by immunoblotting. A bioluminescent ovarian cancer xenograft model was used to determine the effect of resveratrol in vivo. A2780 ovarian cancer cells stably expressing green fluorescent protein were injected into the peritoneal cavity of female nu/nu mice. After tumor establishment, mice were treated with vehicle control, cisplatin, or resveratrol. Tumor response was monitored on a light box. Results: Glucose deprivation and resveratrol induced cell death in all ovarian cell lines by 24 h. Resveratrol inhibited glucose uptake, AKT activation and translocation of the Glut1 receptor to the plasma membrane. Mice treated with cisplatin and resveratrol had a complete response to treatment, whereas control mice developed carcinomatosis. Conclusions: Resveratrol inhibits glucose uptake in ovarian cancer cells and induces autophagocytosis. The majority of conventional chemotherapeutic agents induce apoptotic cell death. Because resveratrol can circumvent chemoresistance due to alterations in apoptotic signaling, it has the potential to be effective against chemoresistant disease. Furthermore, because ovarian cancer cells are dependent upon glucose for survival, agents that inhibit glycolysis, such as resveratrol, may have significant therapeutic benefit for ovarian cancer patients.
IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling
Authors: Andrew N. Wilkinson, Karshing Chang, Rachel D. Kuns, Andrea S. Henden, Simone A. Minnie, Kathleen S. Ensbey, Andrew D. Clouston, Ping Zhang, Motoko Koyama, Juan Hidalgo, Stefan Rose-John, Antiopi Varelias, Slavica Vuckovic, Kate H. Gartlan, Geoffrey R. Hill
Journal: Blood (2019)
Methylguanine DNA methyl transferase (MGMT) expression to predict response to temozolomide (TMZ) in patients with digestive neuroendocrine tumors (NETs).
Authors: Pascal Hammel, Olivia Hentic, Jerome Cros, Vinciane Rebours, Magaly Zappa, Frederique Maire, Philippe Ruszniewski, Anne Couvelard
Journal: Journal of Clinical Oncology (2012)

4133 Background: TMZ is an orally given drug used in patients (pts) with NETs, with encouraging results in pancreatic NETs in a recent study (Strosberg et al, 2011). Higher treatment efficacy seems to be correlated to MGMT tumor deficiency (Kulke et al, 2010). Aim-To assess MGMT expression in digestive NETs and to correlate with the efficacy of TMZ-based therapies. Methods: All pts with well differentiated, progressive, non resectable NETs treated with TMZ-based chemotherapy were included. Treatment efficacy was defined according to RECIST. Pts with progression or only stable disease were considered as “non-responders”. Nuclear expression of MGMT was assessed by immunohistochemistry on primary tumors or metastases and graded according the product of the intensity of staining (0 to 3) and the rate of positive cells (%), leading to a score comprised between 0 and 300. A score ≥ 80 was defined as “high” staining. Results: 22 pts (age 59 years (36-81)) with pancreatic (14 pts), small bowel (5 pts) or other (3 pts) NETs, grade 1 (5 pts) or 2 (17 pts) (WHO 2010 classification) were included. They received TMZ alone (19 pts) or combined with capecitabine (3 pts) as first line (3 pts) or 2+ line (19 pts).After a median of 6 cycles (3-16), objective response, stable disease and progression rates were seen in 32 % (7 pts, all with pancreatic NETs), 41% (9 pts, 5 pancreatic) and 27% (6 pts, 4 small bowel), respectively. Median (range) MGMT score was 10 (0-300). A “High” MGMT score was seen in 36% of pts (small bowel 4, pancreas 3 pts) ; it was correlated with primary tumor location (more frequent in small bowel NETs, p=0.02) and predictive of the absence of response (p=0.02). A “Low “MGMT score tended to be associated with objective response (p=0.06) whereas none of the pts with “high” score had tumor response. Response rate in pts with “low” MGMT score was 50%. Conclusions: MGMT deficiency is more frequent in pancreatic than small bowel NETs. Patients with pancreatic NET and low MGMT score are good candidates for TMZ, whereas those with high score should be treated with other drug in first intention. In patients with small bowel NET with most often high MGMT score, tumor stabilization using TMZ seems to be rare.
DIASTOLIC PULMONARY GRADIENT PREDICTS RIGHT VENTRICULAR FAILURE AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
Authors: Hilmi Alnsasra, Rabea Asleh, Sarah Schettle, Naveen Pereira, Robert Frantz, Brooks Edwards, Alfredo Clavell, Simon Maltais, Richard Daly, John Stulak, Andrew Rosenbaum, Atta Behfar, Sudhir Kushwaha
Journal: Journal of the American College of Cardiology (2019)
Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Authors: S.V. Liu, M. Duruisseaux, K. Tolba, E. Branden, Y. Goto, B.A. Weinberg, D.J. Renouf, R.C. Doebele, C. Heining, R.F. Schlenk, P.K. Cheema, J. Cadranel, M.R. Jones, A.E. Drilon, D. Trombetta, L.A. Muscarella, A. Cseh, F. Solca, J.J. Laskin
Journal: Annals of Oncology (2019)
Abstract 16095: Treatment Gap of Statin Therapy in Patients Hospitalized With a New Diagnosis of Atherosclerotic Cardiovascular Disease (ASCVD) Within a Large Integrated Healthcare Institution: The IMPRES Study
Authors: Heidi T May, Tami L Bair, Kirk U Knowlton, Jeffrey L Anderson, Donald L Lappé, Joseph B Muhlestein
Journal: Circulation (2017)

Introduction: Guidelines recommend that all patients with ASCVD, which include coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD), should be prescrib...
Metalloproteases Could Be Involved in Erythroid Differenciation in MPN
Authors: Miguel Gallardo, Santiago Barrio, Ana Jimenez, Oscar Toldos, Rosa-Maria Garcia-Martin, Enriqueta Albizua, Rosa M. Ayala, Inmaculada Rapado, Marisa Candelas, Santiago Redondo, Florinda Gilsanz, Joaquín Martínez-López
Journal: Blood (2011)
Von Willebrand Disease: From In Vivo to In Vitro Disease Models
Authors: Suzan de Boer, Jeroen Eikenboom
Journal: HemaSphere (2019)

Abstract Von Willebrand factor (VWF) plays an essential role in primary hemostasis and is exclusively synthesized and stored in endothelial cells and megakaryocytes. Upon vascular injury, VWF is released into the circulation where this multimeric protein is required for platelet adhesion. Defects of VWF lead to the most common inherited bleeding disorder von Willebrand disease (VWD). Three different types of VWD exist, presenting with varying degrees of bleeding tendencies. The pathophysiology of VWD can be investigated by examining the synthesis, storage and secretion in VWF producing cells. These cells can either be primary VWF producing cells or transfected heterologous cell models. For many years transfected heterologous cells have been used successfully to elucidate many aspects of VWF synthesis. However, those cells do not fully reflect the characteristics of primary cells. Obtaining primary endothelial cells or megakaryocytes with a VWD phenotype, requires invasive procedures, such as vessel collection or a bone marrow biopsy. A more recent and promising development is the isolation of endothelial colony forming cells (ECFCs) from peripheral blood as a true‐to‐nature cell model. Alternatively, various animal models are available but limiting, therefore, new approaches are needed to study VWD and other bleeding disorders. A potential versatile source of endothelial cells and megakaryocytes could be induced pluripotent stem cells (iPSCs). This review gives an overview of models that are available to study VWD and VWF and will discuss novel approaches that can be considered to improve the understanding of the structural and functional mechanisms underlying this disease.
Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors: 36-month results
Authors: K. Sakaguchi, K. Nakatsukasa, H. Koyama, T. Matsuda, M. Kato, Y. Ouchi, M. Morita, T. Taguchi
Journal: Annals of Oncology (2019)
Homogenisation of leftover surgical tissue across multiple cancer types: A feasibility study (HoLST-F)
Authors: L. Spain, L. Gallegos, Z. Tippu, S. Hill, K. Litchfield, L. Au, A. Gilchrist, V. Primus, A. Barhoumi, S. Stanislaw, S. Agrawal, N. Shaikh, N. Patel, M.-F. Mendoza, G. Noel-Storr, J.M.G. Larkin, N. Alexander, S. Turajlic
Journal: Annals of Oncology (2019)
Health-Related Values and Preferences Regarding Meat Consumption
Authors: Claudia Valli, Montserrat Rabassa, Bradley C. Johnston, Ruben Kuijpers, Anna Prokop-Dorner, Joanna Zajac, Dawid Storman, Monika Storman, Malgorzata M. Bala, Ivan Solà, Dena Zeraatkar, Mi Ah Han, Robin W.M. Vernooij, Gordon H. Guyatt, Pablo Alonso-Coello
Journal: Annals of Internal Medicine (2019)

This article has been corrected. The original version (PDF) is appended to this article as a Supplement. Background: A person's meat consumption is often determined by their values and preferences. Purpose: To identify and evaluate evidence addressing health-related values and preferences regarding meat consumption. Data Sources: MEDLINE, EMBASE, Web of Science, Centre for Agriculture and Biosciences Abstracts, International System for Agricultural Science and Technology, and Food Science and Technology Abstracts were searched from inception to July 2018 without language restrictions. Study Selection: Pairs of reviewers independently screened search results and included quantitative and qualitative studies reporting adults' health-related values and preferences regarding meat consumption. Data Extraction: Pairs of reviewers independently extracted data and assessed risk of bias. Data Synthesis: Data were synthesized into narrative form, and summaries were tabulated and certainty of evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Of 19 172 initial citations, 41 quantitative studies (38 addressed reasons for meat consumption and 5 addressed willingness to reduce meat consumption) and 13 qualitative studies (10 addressed reasons for meat consumption and 4 addressed willingness to reduce meat consumption) were eligible for inclusion. Thirteen studies reported that omnivores enjoy eating meat, 18 reported that these persons consider meat an essential component of a healthy diet, and 7 reported that they believe they lack the skills needed to prepare satisfactory meals without meat. Omnivores are generally unwilling to change their meat consumption. The certainty of evidence was low for both "reasons for meat consumption" and "willingness to reduce meat consumption in the face of undesirable health effects." Limitation: Limited generalizability of findings to lower-income countries, low-certainty evidence for willingness to reduce meat consumption, and limited applicability to specific types of meat (red and processed meat). Conclusion: Low-certainty evidence suggests that omnivores are attached to meat and are unwilling to change this behavior when faced with potentially undesirable health effects. Primary Funding Source: None. (PROSPERO: CRD42018088854)
A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)
Authors: M.T. Campbell, S. Martin, A.L. Tam, R.A. Sheth, S. Singh, K. Ahrar, B. Slack Tidwell, P. Rao, J.A. Karam, C.G. Wood, N.M. Tannir, E. Jonasch, J. Gao, A.Y. Shah, J.M. Blando, F. Duan, S. Basu, J. Allison, P. Sharma, S. Singh
Journal: Annals of Oncology (2019)
Phase II study: Letrozole maintenance therapy after first-line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Authors: A. Tyulyandina, A. Rumyantsev, I. Pokataev, V. Nechushkina, K. Morkhov, Y. Sergeev, V. Mochalnikova, A. Bulanov, M. Stenina, S. Tjulandin
Journal: Annals of Oncology (2019)
A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in epithelioid hemangioendothelioma (EHE) patients
Authors: M.E. Weidema, O. Husson, W.T. van der Graaf, H. Leonard, B.H. de Rooij, L Hartle De Young, I.M.E. Desar, L.V. van de Poll-Franse
Journal: Annals of Oncology (2019)
SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Authors: T. Andre, M.P. Saunders, A. Kanehisa, E. Gandossi, R. Fougeray, N. Causse-Amellal, A. Falcone
Journal: Annals of Oncology (2019)
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: 10-year follow-up of West Japan thoracic oncology group WJTOG0105
Authors: Y. Zenke, M. Tsuboi, Y. Chiba, M. Satouchi, S. Mitsuoka, J. Shimizu, H. Daga, D. Fujimoto, M. Mori, T. Aoki, T. Sawa, S. Omori, H. Saka, Y. Iwamoto, M. Okuno, T. Hirashima, K. Kshiwabara, M. Tachihara, N. Yamamoto, K. Nakagawa
Journal: Annals of Oncology (2019)
Worse patient- physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the palliative care working committee of the Turkish Oncology Group (TOG)
Authors: A. Alkan, A. Yaşar, Z.G. Güç, M. Gürbüz, T. Başoğlu, S. Sezgin Göksu, F. Buğdaycı Başal, H.M. Türk, Ö Özdemir, H. Yeşil Çınkır, D.C. Güven, T. Kuş, S. Türker, L. Koral, Y. Karakaş, N. Ak, S. Paydaş, E. Karcı, Ö Tanrıverdi, F. Çay Şenler
Journal: Annals of Oncology (2019)
Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Authors: L. Albiges, B.I. Rini, J B A G Haanen, R.J. Motzer, C.K. Kollmannsberger, S. Negrier, F. Nole, J. Bedke, M.A. Bilen, P. Nathan, Y. Tomita, B. Huang, K.A. Ching, A. Chudnovsky, P.B. Robbins, A. di Pietro, D. Thomaidou, T.K. Choueiri
Journal: Annals of Oncology (2019)
Correlation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival
Authors: A Gasol Cudos, S Morales Murillo, J Veas Rodriguez, J F Córdoba Ortega, M I Gil García, C Canosa Morales, J Melé Olivé, I. el Koulali, E Iglesias Martínez
Journal: Annals of Oncology (2019)
Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Authors: J. Hubbard, C. Cremolini, R.P. Graham, R. Moretto, J. Mitchell, J. Wessling, E.R. Tőke, Z. Csiszovszki, O. Lorincz, L. Molnar, E. Somogyi, M. Megyesi, K. Pántya, J. Toth, P. Pales, I. Miklos, A. Falcone
Journal: Annals of Oncology (2019)
Clinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients
Authors: X. Du, F. Li, G. Lizee, P. Hwu, L. Deng, A. Talukder, D. Hawke, Q. Zou, J. Roszik, M. Stairs, W. Feng, K. Jackson, C. Chen, M. Zhang, C. Huo, Y. Chiu, Y. Wang, S. Zhou, Y. Zhang, J. Xu
Journal: Annals of Oncology (2019)
Contribution of adipogenesis to healthy adipose tissue expansion in obesity
Authors: Lavanya Vishvanath, Rana K. Gupta
Journal: Journal of Clinical Investigation (2019)

The manner in which white adipose tissue (WAT) expands and remodels directly impacts the risk of developing metabolic syndrome in obesity. Preferential accumulation of visceral WAT is associated with increased risk for insulin resistance, whereas subcutaneous WAT expansion is protective. Moreover, pathologic WAT remodeling, typically characterized by adipocyte hypertrophy, chronic inflammation, and fibrosis, is associated with insulin resistance. Healthy WAT expansion, observed in the “metabolically healthy” obese, is generally associated with the presence of smaller and more numerous adipocytes, along with lower degrees of inflammation and fibrosis. Here, we highlight recent human and rodent studies that support the notion that the ability to recruit new fat cells through adipogenesis is a critical determinant of healthy adipose tissue distribution and remodeling in obesity. Furthermore, we discuss recent advances in our understanding of the identity of tissue-resident progenitor populations in WAT made possible through single-cell RNA sequencing analysis. A better understanding of adipose stem cell biology and adipogenesis may lead to novel strategies to uncouple obesity from metabolic disease.
Systematic inflammation and histologic grade in non-small cell lung carcinoma
Authors: K. Tsapakidis, N. Tsoukalas, C. Giaginis, I. Gioulbasanis, M. Tolia, E. Aravantinou, M. Galanopoulos, M. Kiakou, I. Kostakis, I. Litos, M. Liontos, E. Sogka, V. Tzouda, K. Liaskonis, S. Theocharis
Journal: Annals of Oncology (2017)
Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Authors: J.-H. Ahn, K.S. Lee, K.-H. Lee, J.H. Seo, S.Y. KANG, J. Sohn, Y. Yang, K.H. Park, Y.W. Moon, S.T. Lim, K.E. Yoon, H.J. Cho, S.-B. Kim
Journal: Annals of Oncology (2019)
Drug firms colluded to hike fludrocortisone price by 1800%, says watchdog
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Three drug companies signed an illegal agreement that resulted in price hikes of up to 1800% for an essential medicine, concludes a provisional finding from the UK’s competition watchdog.

In a “statement of objections” issued on 3 October, the UK Competition and Markets Authority set out its provisional view that, in 2016, the drug company Aspen unlawfully agreed to pay two other firms, Amilco and Tiofarma, to stay out of the UK market for fludrocortisone acetate tablets, a prescription only medicine mainly used to treat Addison’s disease.

The alleged illegal agreement protected Aspen’s UK monopoly to supply the drug to the NHS and enabled the company to increase …
HER2 inhibition in aggressive squamous cell carcinomas driven by a common MET sema domain polymorphism
Authors: N.A. Mohamed Salleh, L.R. Kong, Y. Huang, J. Ho, J.S. Lim, S.G. Lim, R.A. Soo, D. Kappei, S.C. Lee, B.-C. Goh
Journal: Annals of Oncology (2019)
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
Authors: Even H. Rustad, Kristine Misund, Elsa Bernard, Eivind Coward, Venkata D. Yellapantula, Malin Hultcrantz, Caleb Ho, Dickran Kazandjian, Neha Korde, Sham Mailankody, Jonathan J. Keats, Theresia Akhlaghi, Aaron D. Viny, David J. Mayman, Kaitlin Carroll, Minal Patel, Christopher A. Famulare, Davine Hofste op Bruinink, Kasey Hutt, Austin Jacobsen, Ying Huang, Jeffrey E. Miller, Francesco Maura, Elli Papaemmanuil, Anders Waage, Maria E. Arcila, Ola Landgren
Journal: American Journal of Hematology (2019)

Abstract Minimal residual disease (MRD) tracking, by next generation sequencing of immunoglobulin sequences, is moving towards clinical implementation in multiple myeloma. However, there is only sparse information available to address whether clonal sequences remain stable for tracking over time, and to what extent light chain sequences are sufficiently unique for tracking. Here, we analyzed immunoglobulin repertoires from 905 plasma cell myeloma and healthy control samples, focusing on the third complementarity determining region (CDR3). Clonal heavy and/or light chain expression was identified in all patients at baseline, with one or more subclones related to the main clone in 3.2%. In 45 patients with 101 sequential samples, the dominant clonal CDR3 sequences remained identical over time, despite differential clonal evolution by whole exome sequencing in 49% of patients. The low frequency of subclonal CDR3 variants, and absence of evolution over time in active multiple myeloma, indicates that tumor cells at this stage are not under selective pressure to undergo antibody affinity maturation. Next, we establish somatic hypermutation and non‐templated insertions as the most important determinants of light chain clonal uniqueness, identifying a potentially trackable sequence in the majority of patients. Taken together, we show that dominant clonal sequences identified at baseline are reliable biomarkers for long‐term tracking of the malignant clone, including both IGH and the majority of light chain clones.
Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma
Authors: Victor H Jimenez-Zepeda, Christopher P. Venner, Andrew Belch, Irwindeep Sandhu, Tatiana Nikitina, Joanne D Hewitt, Peter Duggan, Paola Neri, Fariborz Rashid-Kolvear, Nizar J Bahlis
Journal: Blood (2015)
A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Authors: F. de Marinis, H. Tu, K.K. Laktionov, J. Feng, A. Poltoratskiy, J. Zhao, I. Egorova, E.-H. Tan, M. Gottfried, V. Lee, D.M. Kowalski, C.-T. Yang, B.J. Srinivasa, A. Passaro, L. Clementi, W. Tang, D C-L Huang, A. Cseh, C. Zhou, Y.-L. Wu
Journal: Annals of Oncology (2019)
Abstract 14960: Delayed Therapy With a Hydrogen Sulfide Donor Improves Exercise Capacity in Heart Failure via Reducing Renal Sympathetic Outflow and RAAS Activation
Authors: Zhen Li, Jianming Kang, Ming Xian, David J Lefer
Journal: Circulation (2018)

Background and Hypothesis: Hydrogen sulfide (H2S) protects against heart failure (HF) by ameliorating oxidative stress, improving mitochondrial function, increasing nitric oxide bioavailability, an...
High NAMPT expression and anti-tumour activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Authors: T. Kozako, T. Ohsugi, Y.-I. Uchida, M. Yoshimitsu, K. Ishitsuka, N. Kato, K. Sato, A. Aikawa, S.-I. Honda
Journal: Annals of Oncology (2019)
Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)
Authors: P. Robelin, M. Tod, O. Colomban, I.L. Ray-Coquard, G. De Rauglaudre, J. Florence, A. Chevalier, P. combe, A. Lortholary, S. Hamizi, N. Raban, G. Ferron, J. Meunier, D. Berton-Rigaud, J. Alexandre, M.-C. Kaminsky-Forrett, C. Dubot, A. Leary, E. Malaurie, B. You
Journal: Annals of Oncology (2019)
Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment
Authors: J.A. Ledermann, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A.R. Clamp, G. Scambia, A. Leary, R.W. Holloway, M Amenedo Gancedo, P.C. Fong, J.C. Goh, D.M. O’Malley, T. Cameron, L. Maloney, S. Goble, R.L. Coleman
Journal: Annals of Oncology (2019)